Amgen pushes back against regulators seeking to pull a key drug, while Pfizer faces investor skepticism over its obesity candidate. Meanwhile, Merck details an ambitious plan to offset the looming patent cliff of its blockbuster Keytruda and reach $70 billion in annual sales.
Pfizer reported a mixed fourth quarter, beating internal financial targets while navigating a post-COVID revenue decline. The pharmaceutical giant spotlighted strong growth from new products and a promising monthly obesity drug candidate, even as it braces for a wave of patent expirations and reaffirms its 2026 outlook.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility dedicated to next-generation weight-loss drugs, signaling a long-term strategic commitment to the obesity market amid intense competition.
Pfizer's once-monthly injectable obesity treatment, PF-3944, demonstrated significant weight loss in a Phase 2b study, positioning the pharmaceutical giant to challenge market leaders Novo Nordisk and Eli Lilly. The company plans an expansive Phase 3 program starting in 2026.
Pfizer has announced positive Phase 2b results for its injectable obesity treatment, reporting significant weight reduction and a favorable safety profile as it gears up for a broad late-stage clinical program.
Pfizer's promising mid-stage trial results for its monthly injectable obesity drug, Metsera, signal a credible new competitor for market leaders Novo Nordisk and Eli Lilly, prompting analysts to flag intensifying rivalry in the lucrative weight-loss therapeutics sector.
Amgen's fourth-quarter earnings surpassed analyst forecasts, driven by strong performance across its key brands and promising progress in its late-stage pipeline, particularly the obesity candidate Meritide.
Positive mid-stage trial results for Pfizer's once-monthly obesity injection, acquired via Metsera, pave the way for a massive late-phase program. The move signals a strategic pivot towards the booming weight-loss drug market as the pharma giant navigates post-pandemic revenue declines.
While Novo Nordisk and Eli Lilly dominate the booming obesity drug market, clinical-stage biotech Viking Therapeutics is emerging as a speculative but potentially transformative investment for those willing to embrace risk.
Pfizer Inc. reported stronger-than-expected Q4 and full-year 2025 results, returning $9.8 billion to shareholders. The pharmaceutical giant is navigating a pivotal transition, leveraging recent acquisitions and a promising obesity drug pipeline to offset upcoming patent expirations and drive growth beyond 2028.
Early clinical results for Pfizer's acquired obesity drug PF-3944 show it may fall short of the high bar set by market leaders, raising questions about its competitive edge in the lucrative weight-loss market.
AstraZeneca has entered a strategic collaboration with China's CSPC Pharmaceutical Group to co-develop and commercialize a portfolio of next-generation therapies for obesity and type 2 diabetes, significantly expanding its weight management pipeline.
InSilico Medicine Cayman TopCo's shares have rocketed over 60% in a month, forcing investors to scrutinize whether its AI-driven drug discovery promise can justify the momentum, especially against a backdrop of persistent losses and a negative book value.
Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
Eli Lilly's CEO sees Medicare's new policy covering obesity treatments as a pivotal moment, poised to unlock access for millions of beneficiaries to its incoming oral drug, orforglipron, and intensify the market battle with Novo Nordisk.
BeOne Medicines extends its collaboration with quantitative systems pharmacology firm InSysBio, aiming to optimize clinical trial dosing and mitigate cytokine release syndrome risks across its broad portfolio of 15 novel oncology assets.
BeOne Medicines (NasdaqGS: ONC) has significantly expanded its strategic partnership with systems biology firm InSysBio. The deepened collaboration aims to leverage advanced mechanistic modeling to de-risk clinical trial design, with a particular focus on optimizing dosing and preempting safety challenges like cytokine release syndrome in oncology studies.
BeOne Medicines (ONC) presents a complex picture for investors, with recent short-term volatility contrasting sharply with strong long-term returns. As the stock trades around $340, analysts debate whether its current price fully reflects the ambitious growth narrative in its oncology pipeline.
Regeneron Pharmaceuticals is positioning its experimental obesity drug, olatorepatide, as a potential game-changer by combining significant weight loss with a dramatic reduction in 'bad' cholesterol. The company believes this dual benefit could carve out a unique niche in the competitive $150 billion market, currently led by Novo Nordisk and Eli Lilly.
Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.
